Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $532000.0.

  • Autolus Therapeutics' Tax Provisions rose 231818.18% to $532000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 1115853.66%. This contributed to the annual value of $1.5 million for FY2024, which is 814210.53% up from last year.
  • Autolus Therapeutics' Tax Provisions amounted to $532000.0 in Q3 2025, which was up 231818.18% from $397000.0 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Tax Provisions high stood at $5.4 billion for Q3 2021, and its period low was -$17.4 million during Q4 2021.
  • For the 5-year period, Autolus Therapeutics' Tax Provisions averaged around $284.4 million, with its median value being $40000.0 (2023).
  • Its Tax Provisions has fluctuated over the past 5 years, first soared by 6836789.57% in 2021, then plummeted by 32000.0% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Tax Provisions (Quarter) stood at -$17.4 million in 2021, then soared by 212.58% to $19.6 million in 2022, then plummeted by 100.12% to -$24000.0 in 2023, then surged by 6191.67% to $1.5 million in 2024, then tumbled by 63.61% to $532000.0 in 2025.
  • Its Tax Provisions was $532000.0 in Q3 2025, compared to $397000.0 in Q2 2025 and $2.2 million in Q1 2025.